These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 10483134

  • 1. [Adverse effects of anti-thymocyte globulin/anti-lymphocyte globulin therapy].
    Kobayashi R, Kaneda M, Watanabe N, Iguchi A, Cho Y, Yoshida M, Arioka H, Naito H, Shikano T, Ishikawa Y.
    Rinsho Ketsueki; 1999 Jul; 40(7):531-5. PubMed ID: 10483134
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Treatment of aplastic anemia with anti-thymocyte globulin and cyclosporine].
    Ohnishi S, Nakagawa M, Kobayashi N, Ogasawara M, Kiyama Y, Naohara T, Higa T, Kasai M.
    Rinsho Ketsueki; 1998 Sep; 39(9):640-4. PubMed ID: 9796396
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of rabbit antithymocyte globulin and Jurkat cell-reactive anti-T lymphocyte globulin as a first-line treatment for children with aplastic anemia.
    Xie X, Shi W, Zhou X, Shao Y, Qiao X.
    Exp Hematol; 2014 Jun; 42(6):431-8. PubMed ID: 24582815
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
    Kröger N, Zabelina T, Renges H, Krüger W, Kordes U, Rischewski J, Schrum J, Horstmann M, Ayuk F, Erttmann R, Kabisch H, Zander AR.
    Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cytokine production during myeloablative and reduced intensity therapy before allogeneic stem cell transplantation.
    Remberger M, Sundberg B.
    Haematologica; 2004 Jun; 89(6):710-6. PubMed ID: 15194539
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
    Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, Erttmann R, Kröger N, Zander AR.
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
    [Abstract] [Full Text] [Related]

  • 15. ALG/ATG treatment--a useful alternative for BMT in selected aplastic anaemia patients.
    Pawelski S, Rokicka-Milewska R, Obłakowski P, Skwarska E, Takiel M, Karpowicz M, Zduńczyk A, Brodzki LM, Leszko B.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989 Aug; 116(3-4):377-81. PubMed ID: 2480277
    [Abstract] [Full Text] [Related]

  • 16. A comparison of Jurkat cell-reactive anti-T lymphocyte globulin and fetal anti-thymocyte globulin preparations in the treatment of aplastic anemia.
    Serefhanoglu S, Buyukasik Y, Purnak T, Goker H, Sayinalp N, Haznedaroglu IC, Ozcebe OI.
    Med Princ Pract; 2011 Aug; 20(4):341-4. PubMed ID: 21576994
    [Abstract] [Full Text] [Related]

  • 17. Anti-lymphocyte globulin therapy in aplastic anaemia--a university hospital experience.
    Leong KW, Teh A, Bosco JJ, Jayaranee S, Sadat U.
    Med J Malaysia; 1995 Jun; 50(2):158-61. PubMed ID: 7565186
    [Abstract] [Full Text] [Related]

  • 18. Anti-lymphocyte globulin therapy in acquired aplastic anaemia.
    Agarwal MB, Agarwal UM, Bhave AB, Vishwanathan C.
    J Assoc Physicians India; 1993 Jun; 41(6):371-3. PubMed ID: 8005976
    [Abstract] [Full Text] [Related]

  • 19. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
    Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C, Quinlan D, Stewart D.
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
    [Abstract] [Full Text] [Related]

  • 20. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
    Hartwig UF, Winkelmann N, Wehler T, Kreiter S, Schneider PM, Meyer RG, Ullmann AJ, Huber C, Kolbe K, Herr W.
    Ann Hematol; 2005 May; 84(5):331-8. PubMed ID: 15726363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.